erteberel,
LY500307,
Erteberel,
533884-09-2,
LY500307,
UNII-2ZUL6758TZ,
Erteberel (LY500307),
(3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol,
2ZUL6758TZ,
Benzopyran derivative., 4b(racemate),
(3aS,4R,9bR)-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta(c)(1) benzopyran-8-ol,
I0G,
Erteberel [USAN:INN],
SERBA-1,
2i0g,
2i0j,
Erteberel (USAN/INN),
LY 500307,
LY-500307,
CHEMBL278703,
PBLJ0575,
SCHEMBL14102383,
BDBM19968,
DTXSID70201547,
EX-A157,
BCPP000173,
ABP000948,
ZINC12353762,
AKOS027323752,
BCP9000889,
DB07933,
SB16682,
NCGC00346557-01,
NCGC00346557-02,
HY-18295,
LY500307/,
CS-0007402,
X7545,
D09899,
Z-3119,
LY 500307,LY-500307, 533884-09-2,
(3aS,4R,9bR)-1,2,3,3a,4,9b-Hexahydro-4-(4-hydroxyphenyl)cyclopenta[c][1]benzopyran-8-ol,
(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0;{2,6}]trideca-1(13),9,11-trien-12-ol,
(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0;{2,6}]trideca-1(9),10,12-trien-12-ol,
(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(13),9,11-trien-12-ol,
(2R,6S,7R)-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-12-ol,
Cyclopenta(c)(1)benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aS,4R,9bR)-,
racemic mixture,
Erteberel [USAN],
D0R2SK,
ER beta agonist (BPH), Lilly,
C18H18O3,
CID10286159,
Lead estrogen receptor beta agonists (benign prostatic hyperplasia),Eli Lilly,